Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daryl D Depestel

Showing results (31-40 of 49) with videos related to

Pageof 5
Sort By:
Open Forum Infectious Diseases|July 3, 2019
Comparison of the In Vitro Susceptibility of Ceftolozane-Tazobactam With the Cumulative Susceptibility Rates of Standard Antibiotic Combinations When Tested Against <i>Pseudomonas aeruginosa</i> From ICU Patients With Bloodstream Infections or PneumoniaDee Shortridge, Michael A Pfaller, S J Ryan Arends, et al.
Pharmacotherapy|August 19, 2003
Linezolid clearance during continuous venovenous hemodiafiltration: a case reportMichael D Kraft, Deborah A Pasko, Daryl D DePestel, et al.
Antimicrobial Agents and Chemotherapy|March 29, 2019
A Combination Antibiogram Evaluation for <i>Pseudomonas aeruginosa</i> in Respiratory and Blood Sources from Intensive Care Unit (ICU) and Non-ICU Settings in U.S. HospitalsLaura Puzniak, Daryl D DePestel, Arjun Srinivasan, et al.
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|February 6, 2010
Drug costs and utilization after implementation of a posaconazole prophylaxis protocol in adults with acute myelogenous leukemiaCarrie W Nemerovski, Emily R Mackler, Daryl D DePestel, et al.
Blood Purification|July 1, 2010
Modeled dalbavancin transmembrane clearance during intermittent and continuous renal replacement therapiesA Mary Vilay, Krishna H Shah, Mariann D Churchwell, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 5, 2020
In Vitro Activity of Imipenem/Relebactam and Ceftolozane/Tazobactam Against Clinical Isolates of Gram-negative Bacilli With Difficult-to-Treat Resistance and Multidrug-resistant Phenotypes-Study for Monitoring Antimicrobial Resistance Trends, United States 2015-2017James A Karlowsky, Sibylle H Lob, Janet Raddatz, et al.
Journal of the American Pharmacists Association : Japha|July 26, 2008
Cephalosporin use in treatment of patients with penicillin allergiesDaryl D DePestel, Michael S Benninger, Larry Danziger, et al.
Open Forum Infectious Diseases|July 26, 2021
Ceftolozane/Tazobactam and Imipenem/Relebactam Cross-Susceptibility Among Clinical Isolates of <i>Pseudomonas aeruginosa</i> From Patients With Respiratory Tract Infections in ICU and Non-ICU Wards-SMART United States 2017-2019Sibylle H Lob, Daryl D DePestel, C Andrew DeRyke, et al.
Infection Control and Hospital Epidemiology|April 5, 2011
Evaluation of hospital room assignment and acquisition of Clostridium difficile infectionMegan K Shaughnessy, Renee L Micielli, Daryl D DePestel, et al.
Critical Care Medicine|October 5, 2010
Daptomycin pharmacokinetics in critically ill patients receiving continuous venovenous hemodialysisA Mary Vilay, Maricor Grio, Daryl D Depestel, et al.
Pageof 5

Showing results (31-40 of 49) with videos related to

Sort By:
Pageof 5
Open Forum Infectious Diseases|July 3, 2019
Comparison of the In Vitro Susceptibility of Ceftolozane-Tazobactam With the Cumulative Susceptibility Rates of Standard Antibiotic Combinations When Tested Against <i>Pseudomonas aeruginosa</i> From ICU Patients With Bloodstream Infections or PneumoniaDee Shortridge, Michael A Pfaller, S J Ryan Arends, et al.
Pharmacotherapy|August 19, 2003
Linezolid clearance during continuous venovenous hemodiafiltration: a case reportMichael D Kraft, Deborah A Pasko, Daryl D DePestel, et al.
Antimicrobial Agents and Chemotherapy|March 29, 2019
A Combination Antibiogram Evaluation for <i>Pseudomonas aeruginosa</i> in Respiratory and Blood Sources from Intensive Care Unit (ICU) and Non-ICU Settings in U.S. HospitalsLaura Puzniak, Daryl D DePestel, Arjun Srinivasan, et al.
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|February 6, 2010
Drug costs and utilization after implementation of a posaconazole prophylaxis protocol in adults with acute myelogenous leukemiaCarrie W Nemerovski, Emily R Mackler, Daryl D DePestel, et al.
Blood Purification|July 1, 2010
Modeled dalbavancin transmembrane clearance during intermittent and continuous renal replacement therapiesA Mary Vilay, Krishna H Shah, Mariann D Churchwell, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 5, 2020
In Vitro Activity of Imipenem/Relebactam and Ceftolozane/Tazobactam Against Clinical Isolates of Gram-negative Bacilli With Difficult-to-Treat Resistance and Multidrug-resistant Phenotypes-Study for Monitoring Antimicrobial Resistance Trends, United States 2015-2017James A Karlowsky, Sibylle H Lob, Janet Raddatz, et al.
Journal of the American Pharmacists Association : Japha|July 26, 2008
Cephalosporin use in treatment of patients with penicillin allergiesDaryl D DePestel, Michael S Benninger, Larry Danziger, et al.
Open Forum Infectious Diseases|July 26, 2021
Ceftolozane/Tazobactam and Imipenem/Relebactam Cross-Susceptibility Among Clinical Isolates of <i>Pseudomonas aeruginosa</i> From Patients With Respiratory Tract Infections in ICU and Non-ICU Wards-SMART United States 2017-2019Sibylle H Lob, Daryl D DePestel, C Andrew DeRyke, et al.
Infection Control and Hospital Epidemiology|April 5, 2011
Evaluation of hospital room assignment and acquisition of Clostridium difficile infectionMegan K Shaughnessy, Renee L Micielli, Daryl D DePestel, et al.
Critical Care Medicine|October 5, 2010
Daptomycin pharmacokinetics in critically ill patients receiving continuous venovenous hemodialysisA Mary Vilay, Maricor Grio, Daryl D Depestel, et al.
Pageof 5